Holen Sie sich die Stockscreener-App
0.1721
2.00%
0.0022
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.1699
Offen:
$0.1694
24-Stunden-Volumen:
3.08M
Relative Volume:
1.99
Marktkapitalisierung:
$30.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.54M
KGV:
-0.8605
EPS:
-0.2
Netto-Cashflow:
$-29.06M
1W Leistung:
-47.23%
1M Leistung:
-54.89%
6M Leistung:
-76.26%
1J Leistung:
-77.55%
1-Tages-Spanne:
$0.16
$0.1801
1-Wochen-Bereich:
$0.16
$0.3279
52-Wochen-Spanne:
$0.16
$1.07
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Vergleichen Sie CTXR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CTXR | 0.1733 | 30.71M | 0 | -32.54M | -29.06M | -0.20 |
| VRTX | 449.09 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.38 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.39 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.66 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.77 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of Offering - Defense World
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan
What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World
Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.31 - Investing.com
Equities Analysts Set Expectations for CTXR FY2024 Earnings - MarketBeat
What is HC Wainwright’s Forecast for CTXR Q1 Earnings? - Defense World
Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com
Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia
Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat
Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - The Malaysian Reserve
Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma
Citius Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Citius Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com UK
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Is Breakeven Near? - Simply Wall St
Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India
CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com
Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Closing Bell Recap: Citius Pharmaceuticals Inc (CTXR) Ends at 0.37, Reflecting a -8.22 Downturn - The Dwinnex
There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.39 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.39 - Investing.com
Analyzing the Impact of Earnings Reports on Citius Pharmaceuticals Inc Inc. (CTXR) Price Performance - The InvestChronicle
Is Citius Pharmaceuticals Inc (CTXR) a threat to investors? - US Post News
Market Resilience: Citius Pharmaceuticals Inc (CTXR) Finishes Weak at 0.43, Down -2.60 - The Dwinnex
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Market Fluctuations - The InvestChronicle
Point72 DIFC Ltd Makes New $29,000 Investment in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals Inc (CTXR) can make a big difference with a little luck - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com
Post-Trade Analysis: Citius Pharmaceuticals Inc (CTXR) Climbs 0.95, Closing at 0.52 - The Dwinnex
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short Interest - MarketBeat
Citius Pharmaceuticals Inc’s results are impressive - US Post News
Citius Pharmaceuticals extends executive and warrant agreements - Investing.com India
Citius Pharmaceuticals extends executive and warrant agreements By Investing.com - Investing.com South Africa
BCA says a US recession remains the most likely outcome - Investing.com
Armistice Capital LLC Purchases New Position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - MarketBeat
Financial Snapshot: Analyzing Citius Pharmaceuticals Inc (CTXR)’s Key Ratio Metrics - The Dwinnex
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
Cettire shares skyrocket - ShareCafe
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):